• Customized Analysis

Medical Research Collaborative ("MRC") is proud to offer to the following Customized Analysis packages:


Tier 1: Includes the analysis of a single publicly-traded healthcare company, involving up to 40 hrs. of research (including vetting/editing) and the submission of all due diligence to the client, becoming their co-property (meaning that MRC reserves the right to share customized analytical reports with our Data Partners; however, we strictly enforce a minimum 14-day lag before doing so). A Tier 1 analysis will comprehensively cover all micro-cap, many small cap, and even some mid-cap healthcare companies’ pipeline of drug assets, thorough review of IP (including term-length, potential claim refutations, and any ongoing patent challenges), competition, timeline on catalysts, and likelihood of success or failure of planned/ongoing clinical trials. However, a fully comprehensive review will usually not be possible for a number of small-cap, most mid-cap, any nearly all large-cap companies under a Tier 1 analysis. Yet, regardless of complexity of the target company, a Tier 1 analysis will provide an excellent overview with a strong degree of targeted analysis that can inform the client on whether or not to pursue greater due diligence, and in many cases (in particular for micro- and many small-cap companies) should be sufficient on its own.

Common Tier 1 report length: 10 – 15+ pages.


Tier 2: Includes the analysis of one or more publicly-traded healthcare companies, involving up to 80 hrs. of research (including vetting/editing) and the submission of all due diligence to the client, becoming their co-property. A Tier 2 analysis will comprehensively cover any two (and sometimes three) micro-cap companies, nearly any small-cap company, and most mid-cap healthcare companies’ pipeline of drug assets, exhaustive review of IP (including term-length, potential claim refutations, and any ongoing patent challenges), competition, timeline on catalysts, and likelihood of success or failure of planned/ongoing clinical trials. However, a fully comprehensive review will still not usually be possible for many large-cap companies under a Tier 2 analysis; contrariwise, a Tier 2 analysis can sometimes be excessive for a single micro-cap company. Yet, regardless of complexity of the target company, a Tier 2 analysis will provide a highly-detailed and well-nuanced analysis.

Common Tier 2 report length: 20 – 30+ pages


Tier 3: Includes the analysis of one or more publicly-traded healthcare companies, involving approximately 160 hrs. of research (including vetting/editing) and the submission of all due diligence to the client, becoming their co-property. A Tier 3 analysis will comprehensively cover four or more micro-cap companies, multiple small cap companies, one or more mid-cap companies, and any large-cap healthcare companies’ pipeline of drug assets, comprehensive review of IP (including term-length, potential claim refutations, and any ongoing patent challenges), competition, timeline on catalysts, and likelihood of success or failure of planned/ongoing clinical trials. A Tier 3 analysis provides an exceptionally-detailed, deeply nuanced, and exhaustive analysis of all companies covered.

Common Tier 3 report length: 40 – 60+ pages


Included with all customized analyses is up to 1,000 words (for Tier 1) to up to 3,000 words (for Tier 3) of email consultation/correspondence.

Upon purchase, an MRC representative will reach out by email to the account registered to begin dialogue, and then, with your directive, initiate our analysis.

If the appropriate tiering to match the particular company you would like targeted is unclear from the above descriptions, please Contact Us with information on the Company in question, and we will reply with what we feel is the appropriate tier and why.



DISCLAIMER

Research reports, notifications of changes made in the MRC Fund portfolio of positions, or any other content disseminated by MRC are not recommendations to buy, sell, avoid, or sell short any security, and are for informational purposes only; we recommend securing the services of a registered investment advisor (which we are not) and performing your own independent investigations before acting on information from us.

Customized Analysis

  • Product Code: Customized Analysis
  • Availability: In Stock
  • $2,250.00


Payment Profile


Tags: Customized Analysis